Regardless Of Prior Therapies, Velcade Is Superior Over Dexamethasone In Relapsed Multiple Myeloma Patients

Automated News - Automated News

User Rating: / 0
PoorBest 
Exposure to prior myeloma therapies, specifically thalidomide (Thalomid) and autologous stem cell transplants (ASCT), does not influence the superior efficacy of Velcade (bortezomib) compared to dexamethasone (Decadron) in patients with relapsed/refractory myeloma, according to an analysis published in the British Journal of Haematology. Researchers had previously found that Velcade resulted in a better response rate, time to progression, and overall survival compared to dexamethasone in relapsed/refractory myeloma patients. Based on these results, Velcade has become one of the standard treatments for relapsed/refractory myeloma patients. Previous trial results had also shown that Velcade kept its superiority compared to dexamethasone irrespective of the number of prior therapies. H...Keep on reading: Regardless Of Prior Therapies, Velcade Is Superior Over Dexamethasone In Relapsed Multiple Myeloma Patients

Read more: The Myeloma Beacon - News

Comments (0)
Only registered users can write comments!

Users Online

We have 56 guests and 0 members online
No users online.

Recent Forum Topics

 

Myeloma Forums

Facebook Image

Social Bookmark

RSS Syndicator

Feed
Feed

Search Articles

Gallery Preview



Polls

How did you find us?
 

Polls

Did you have a Stem Cell Transplant?
 

Visitors Counter

mod_vvisit_countermod_vvisit_countermod_vvisit_countermod_vvisit_countermod_vvisit_countermod_vvisit_countermod_vvisit_counter
mod_vvisit_counterToday841
mod_vvisit_counterYesterday1259
mod_vvisit_counterThis week5967
mod_vvisit_counterLast week6803
mod_vvisit_counterThis month9922
mod_vvisit_counterLast Month28725
mod_vvisit_counterAll242002

Online (20 minutes ago): 24
Your IP: 38.107.191.80
,
Now is: 2010-09-09 16:16
JoomlaWatch Stats 1.2.9 by Matej Koval



Copyright © 2010 Myeloma Forums. - All Rights Reserved